Differential modulation of IL-4, IL-10, IL-17, and IFN-γ production mediated by IgG from Human T-lymphotropic virus-1 (HTLV-1) infected patients on healthy peripheral T (CD4+, CD8+, and γδ) and B cells.
ATLL
CD4+ T
CD8+ T
HAM/TSP
HTLV-1
IFN-γ
IL-17
IgG
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
06
2023
accepted:
07
08
2023
medline:
15
9
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
epublish
Résumé
Human T-lymphotropic virus 1 (HTLV-1) infected individuals remain as asymptomatic carriers (ACs) or can develop the chronic neurological disorder HTLV-1-associated myelopathy/Tropical Spastic Paraparesis (HAM/TSP) or the adult T-cell leukemia/lymphoma (ATLL), and the immunological mechanisms involved in this pathologies need to be elucidated. Recently, it has been demonstrated that induced or naturally developed IgG repertoires obtained from different groups of donors, grouped by immune status, can modulate human T and B cell functions. Here we aimed to evaluate if the IgG obtained from HTLV-1-infected ACs, HAM/TSP, and ATLL patients can differentially modulate the production of cytokines by human T and B cells. With this purpose, we cultured PBMCs with IgG purified from ACs, HAM/TSP, or ATLL donors and evaluated the frequency and intracellular cytokine production by flow cytometry. Our results indicate that IgG from HAM/TSP patients could induce an augment of IL-17-producing CD4+ T cells, reduce the frequency of IL-4-producing CD4+ T cells, increase IFN-γ-producing CD8+ T cells, and reduce IL-4-producing CD8+ T cells. IgG from ATLL could reduce the frequency of IL-4-producing CD4+ T cells, similarly to IgG from HAM/TSP /TSP, and could reduce the frequency of IFN-γ-producing γδT cells without influence on IL-17- and IL4-producing γδT and could reduce the frequency of IL-10- producing B cells. Finally, IgG from both HAM/TSP and ATLL patients could reduce the frequency of IFN-γ producing B cells. In conclusion, these results suggest that these preparations are active, partly overlapping in their effects, and able to elicit distinct effects on target populations.
Identifiants
pubmed: 37711742
doi: 10.3389/fmed.2023.1239706
pmc: PMC10498471
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1239706Informations de copyright
Copyright © 2023 Machado, Fagundes, Fernandes, Oliveira, Nukui, Casseb, Cunha, Nali, Sanabani and Victor.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Viral Immunol. 2023 Mar;36(2):136-143
pubmed: 36745398
Expert Rev Clin Immunol. 2014 Nov;10(11):1531-46
pubmed: 25340428
Eur Ann Allergy Clin Immunol. 2021 Jul;53(4):161-167
pubmed: 32548997
J Neuroinflammation. 2022 Dec 8;19(1):293
pubmed: 36482436
PLoS Negl Trop Dis. 2019 Dec 18;13(12):e0007705
pubmed: 31851683
Lancet. 1989 Feb 25;1(8635):441
pubmed: 2563817
J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):e56-e60
pubmed: 31714433
Eur Cytokine Netw. 2020 Dec 3;:
pubmed: 33270019
Allergy. 2019 Feb;74(2):395-398
pubmed: 30291622
J Neuropathol Exp Neurol. 2015 Jan;74(1):2-14
pubmed: 25470342
Arq Neuropsiquiatr. 2006 Jun;64(2A):217-21
pubmed: 16791359
AIDS Res Hum Retroviruses. 2006 Oct;22(10):931-5
pubmed: 17067261
Clin Exp Allergy. 2019 Jul;49(7):1000-1012
pubmed: 30929287
Lancet. 1986 May 3;1(8488):1031-2
pubmed: 2871307
Eur J Haematol. 1993 Mar;50(3):133-40
pubmed: 8472809
Int J Dermatol. 2018 Apr;57(4):434-440
pubmed: 29355930
Lancet. 1987 Nov 21;2(8569):1220
pubmed: 2890850
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Allergy Asthma Clin Immunol. 2017 Apr 17;13:22
pubmed: 28428801
Bioengineering (Basel). 2022 Oct 06;9(10):
pubmed: 36290496
Eur J Haematol. 1996 Apr;56(4):241-7
pubmed: 8641393
PLoS One. 2017 Apr 4;12(4):e0174869
pubmed: 28376092
Microbiol Immunol. 2022 Oct;66(10):460-464
pubmed: 35924689
J Gen Virol. 2021 Sep;102(9):
pubmed: 34494950
AIDS Res Hum Retroviruses. 2017 Nov;33(11):1134-1139
pubmed: 28648091
J Cell Biochem. 2018 May;119(5):3968-3979
pubmed: 29227540
PLoS Pathog. 2012 Jan;8(1):e1002480
pubmed: 22291590
Haematologica. 2021 May 01;106(5):1443-1456
pubmed: 33567810
J Immunol Res. 2014;2014:780386
pubmed: 25009823
Lancet. 1985 Aug 24;2(8452):407-10
pubmed: 2863442
Int J Dermatol. 2020 Mar;59(3):359-364
pubmed: 31631342
Arch Immunol Ther Exp (Warsz). 2019 Aug;67(4):263-270
pubmed: 31087106
Immunol Cell Biol. 2020 Aug;98(7):540-548
pubmed: 32342552
Hum Vaccin Immunother. 2017 Mar 4;13(3):507-513
pubmed: 27808600
Mol Neurobiol. 2023 Jul;60(7):3839-3854
pubmed: 36947318
Lancet. 1992 May 2;339(8801):1110-1
pubmed: 1349122
Acta Trop. 2013 Jan;125(1):75-81
pubmed: 23022356
J Neurovirol. 2002 Oct;8(5):359-64
pubmed: 12402162
Viral Immunol. 2017 May;30(4):298-301
pubmed: 28410448
Blood. 1988 Oct;72(4):1182-6
pubmed: 3262383
Allergol Immunopathol (Madr). 2018 Sep - Oct;46(5):454-459
pubmed: 30082063
J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S132-45
pubmed: 8797716
Immunobiology. 2006;211(3):157-66
pubmed: 16530083
Nat Med. 2002 May;8(5):509-13
pubmed: 11984596
Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9
pubmed: 6261256
Hum Vaccin Immunother. 2017 Jul 3;13(7):1563-1572
pubmed: 28441069
Intern Med. 1999 Sep;38(9):717-21
pubmed: 10480302
Sci Rep. 2023 May 11;13(1):7659
pubmed: 37169817
Cells. 2020 Oct 05;9(10):
pubmed: 33027887
Ann Neurol. 1987 Feb;21(2):117-22
pubmed: 2881513
Scand J Immunol. 2018 Dec;88(6):e12721
pubmed: 30403024
Clin Exp Immunol. 2007 Jan;147(1):35-44
pubmed: 17177961
Viruses. 2022 Apr 03;14(4):
pubmed: 35458481
Front Microbiol. 2018 May 18;9:795
pubmed: 29867783
Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5
pubmed: 6979048
Front Immunol. 2019 Oct 11;10:2415
pubmed: 31681303
Vaccines (Basel). 2020 Aug 04;8(3):
pubmed: 32759782